A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Inclusion Criteria: * Cytopathologically or histologically confirmed diagnosis of MM * Measurable disease, as indicated by one or more of the following: * Serum M-protein ≥ 1.0 g/dL * Urine Bence Jones protein ≥ 200 mg/24 hr * Elevated Free Light Chain as per the International Myeloma Working Group (IMWG) criteria * Males and females ≥ 18 years of age * Life expectancy of more than 5 months * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate hepatic function, with bilirubin \< 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3.5 times ULN * Serum Creatinine Clearance(CrCl) ≥ 30 mL/min, either measured or calculated using a standard formula (e.g. Cockcroft and Gault) * Additional Laboratory Requirements * Absolute neutrophil count (ANC) ≥1.0 x 109/L * Hemoglobin ≥8 g/dL \[transfusion permitted\] * Platelet count ≥50.0 x 109/L * Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks * Patients may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines * Written informed consent in accordance with federal, local, and institutional guidelines * Patients must agree to practice contraception * Male patients must agree not to donate semen or sperm. Exclusion Criteria: * Patients with non-secretory or hyposecretory MM * Prior treatment for MM (prior radiation therapy or dexamethasone up to 160 mg for spinal cord compression is allowed. Other limited field radiation involving ≤ 1/3 of the pelvic area is also allowed) * Plasma cell leukemia * Pregnant or lactating females * Major surgery within 21 days prior to first dose * Congestive heart failure (CHF) (New York Heart Association class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months * Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose * Patients receiving active treatment or intervention for any other malignancy or patients who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment. * Serious psychiatric or medical conditions that could interfere with treatment * Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before study treatment * Contraindication to any of the required concomitant drugs, including antiviral (e.g. Valacyclovir) and proton-pump inhibitor (e.g. lansoprazole). Corticosteroid therapy in a dose equivalent to dexamethasone ≥ 1.5 mg/day or prednisone ≥ 10 mg/day. (Steroid use is allowed if necessary to treat spinal cord compression and/or hypocalcaemia.) * Patients in whom the required program of oral and IV fluid hydration is contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment * Patients with primary systemic amyloidosis.